APR 17, 2020 3:29 PM PDT

Gilead's Remdesivir Trial Sees Rapid Recoveries from COVID-19

WRITTEN BY: Annie Lennon

Early results from a Chicago hospital treating patients with Gilead Sciences’ antiviral drug remdesivir for severe cases of COVID-19 as a part of a clinical trial has so far shown that patients are rapidly recovering from fever and respiratory symptoms. Almost all patients treated with the drug are discharged from hospital within a week. 

One of the first drugs suspected to treat COVID-19, clinical trials assessing the drug’s potency have been long awaited. Should these positive results be echoed upon the trial’s completion later this month, the drug may see fast approval by the FDA as the first official treatment against the virus. 

The University of Chicago Medicine recruited 125 people with COVID-19 to partake in Gilead’s two Phase 3 clinical trials. With 113 having severe symptoms of the disease, all patients were treated on a daily basis with remdesivir. Kathleen Mullane, the infectious disease specialists at the university in monitoring the Gilead studies said, “The best news is that most of our patients have already been discharged, which is great. We’ve only had two patients perish.”

With similar trials being run in other institutions around the country, until further results are collected, the initial findings from the study can not be taken as conclusive. Yet, even when the results do emerge, as the study does not contain a control group taking a placebo, it may be difficult to properly assess the efficacy of the drug. 

Despite this, medical practitioners and researchers alike remain hopeful. Mullone says “Certainly when we start [the] drug, we see fever curves falling...Fever is now not a requirement for people to go on trial, we do see when patients do come in with high fevers, they do [reduce] quite quickly. We have seen people come off ventilators a day after starting therapy. So, in that realm, overall our patients have done very well.” 

“Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesn’t have to be 10 days. We have very few that went out to 10 days, maybe three.”

 

Sources: Stat, CNN

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
APR 17, 2020
Chemistry & Physics
APR 17, 2020
Fish Tank Chemicals Aren't COVID-19 Medication, Says FDA
While the medical community is scrambling to find the proper medications for Sars-CoV-02 infection, a significant portio ...
APR 21, 2020
Immunology
APR 21, 2020
A Nasal Vaccine Against Tau Tangles
  One of the hallmarks of Alzheimer’s disease (AD) is the accumulation of “tau tangles”. Tau is a ...
APR 24, 2020
Drug Discovery & Development
APR 24, 2020
Teenage Cannabis Use May Prime the Brain to Enjoy Cocaine
New research has found that teenage cannabis use may make the brain more susceptible to the effects of cocaine. "It ...
APR 17, 2020
Drug Discovery & Development
APR 17, 2020
Overcoming Multi-Drug Resistance in Cancer
Resistance to chemotherapeutic use in caner patients is something that is inevitable. Continued resistance to these drug ...
MAY 04, 2020
Cancer
MAY 04, 2020
A Retroactive Study Finds an Immunotherapy Effective as a Third-Line Therapy
Cancer is a particularly persistent disease. Many therapies are composed of one or more different treatments. These trea ...
MAY 16, 2020
Neuroscience
MAY 16, 2020
Stem Cell Method (Parkinson's) Could Avoid Transplant Rejection
Researchers at McLean Hospital and Massachusetts General Hospital (MGH) have tested a stem cell treatment method that av ...
Loading Comments...